Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03440814 · ClinicalTrials.gov registry record · Phase 3
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
A Phase 3 study, sponsored by Soleno Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
NCT03440814 is a Phase 3 study that has completed, run by Soleno Therapeutics. The registered enrollment target is 127 participants.
The verdict
NCT03440814, a Phase 3 study, has completed, sponsored by Soleno Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.
Interventions
- DRUG DCCR
- DRUG Placebo for DCCR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2020-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03440814
The ClinicalTrials.gov registry entry for NCT03440814 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soleno Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DCCR is the first listed.
NCT03440814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03440814 about?
NCT03440814 is a clinical study titled "A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome". The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.
What is the current status of trial NCT03440814?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2018-05-09. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT03440814?
The interventions under investigation include: DCCR (DRUG), Placebo for DCCR (DRUG).
Who is sponsoring clinical trial NCT03440814?
This trial is sponsored by Soleno Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.